Adam Craig, M.D., Ph.D., Named Vice President and Chief Medical Officer, INNOVIVE Pharmaceuticals Inc.NEW YORK New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of -- INNOVIVE Pharmaceuticals Inc., a biopharmaceutical company headquartered in Manhattan, announced today that Adam R. Craig, M.D., Ph.D., has joined the company as vice president and chief medical officer, effective immediately. Dr. Craig joins INNOVIVE Pharmaceuticals from ArQule Inc. where, as medical director and vice president, clinical development, he established that company's clinical development department and expanded its ability to conduct multiple clinical studies. He was a member of ArQule's executive team. Prior to ArQule, Dr. Craig was senior director, clinical development for Ilex Oncology Inc., where he helped gain the first approval of a pediatric pediatric /pe·di·at·ric/ (pe?de-at´rik) pertaining to the health of children. pe·di·at·ric adj. Of or relating to pediatrics. chemotherapeutic agent in nearly a decade. Dr. Craig also served as medical advisor, oncology for Antisoma plc (London). "Adam Craig's industry and clinical experience make him well equipped to be INNOVIVE's chief medical officer. Among other early duties, Dr. Craig will develop and implement clinical trials for INNO-105, the Opioid Growth Factor which will be studied for its anti-tumor activity in pancreatic cancer," said Steven Kelly, president and chief executive officer, INNOVIVE Pharmaceuticals Inc. INNOVIVE recently licensed worldwide rights for the use of Opioid Growth Factor (OGF OGF Open Gaming Foundation OGF Old Growth Forest OGF Oregongreenfree (online medical marijuana community) OGF Open Grid Forum ) in oncology from Penn State University. Dr. Craig holds bachelor of medicine Noun 1. Bachelor of Medicine - (a British degree) a bachelor's degree in medicine MB bachelor's degree, baccalaureate - an academic degree conferred on someone who has successfully completed undergraduate studies Britain, Great Britain, U.K. and bachelor of surgery degrees from Charing Cross and Westminster Medical School, University of London For most practical purposes, ranging from admission of students to negotiating funding from the government, the 19 constituent colleges are treated as individual universities. Within the university federation they are known as Recognised Bodies , with prizes awarded in oncology and pediatrics. He earned his Ph.D. in molecular medicine at the University of Leeds Organisation Faculties The various schools, institutes and centres of the University are arranged into nine faculties, each with a dean, pro-deans and central functions:
abbr. Master of Business Administration Noun 1. MBA - a master's degree in business Master in Business, Master in Business Administration from the Open University Business School. He is a member of the Royal College of Paediatrics and Child Health Royal College of Paediatrics and Child Health in London is responsible for the training of postgraduate doctors in paediatrics and conducting the MRCPCH membership exams. They also conduct the Diploma in Child Health exam, which is taken by many doctors who plan a career in General , the Royal College of Physicians The Royal College of Physicians of London was the first medical institution in England to receive a Royal Charter. It was founded in 1518 and is one of the most active of all medical professional organisations. of the United Kingdom, the American Society of Clinical Oncology American Society of Clinical Oncology, or ASCO, is an organization that represents all clinical oncologists. Every year, ASCO holds a large symposium where physicians and researchers meet to convey and discuss research and ideas. and the American Society of Hematology. Dr. Craig has authored or co-authored numerous journal articles and abstracts on oncology, including a medical textbook. INNOVIVE Pharmaceuticals Inc. is a privately held biopharmaceutical company headquartered in New York. The company's mission is to acquire, develop and commercialize novel therapeutics addressing significant unmet medical needs in the fields of oncology and hematology. For additional information, visit www.innovivepharma.com. This press release contains forward-looking statements that involve risks and uncertainties that could cause INNOVIVE's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that any of INNOVIVE's development efforts relating to its product candidates will be successful. Other risks that may affect forward-looking information contained in this press release include the possibility of being unable to obtain regulatory approval of INNOVIVE's product candidates, the risk that the results of clinical trials may not support INNOVIVE's claims, INNOVIVE's reliance on third-party researchers to develop its product candidates and its lack of experience in developing pharmaceutical products. INNOVIVE assumes no obligation to update these forward-looking statements, except as required by law. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion